Janssen inks inflammatory disease collaboration with Mestag Therapeutics
Pharma Times
MAY 19, 2021
Collaboration will utilise Mestag’s specialist fibroblast subpopulation biology platform to identify novel therapeutic targets
Sat.May 15, 2021 - Fri.May 21, 2021
123 
Listening to ultra-rare disease communities
pharmaphorum
MAY 21, 2021
When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. As a global commercial biopharmaceutical company pioneering therapies for ultra-rare diseases, PTC Therapeutics is familiar with the challenges. The company prides itself on a patient-centric approach to treatment but there can be significant hurdles in patients accessing potentially life-changing treatments.
Join 33,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Rashedi Hassan takes over Sales & Marketing management of Telstar’s subsidiary in Bangladesh
Pharma Mirror
MAY 19, 2021
Terrassa (Barcelona). Azbil Telstar announces the appointment of Rashedi Hassan as a Sales & Marketing Manager of the subsidiary of the company in Dhaka, Bangladesh. From 14th February 2021, Rashedi Hassan focuses his responsibility on developing extensive marketing and sales plan to strengthen the Telstar brand position in the local pharmaceutical market and to promote the presence and distribution of Telstar branded Life Sciences service & product solutions in the region, particularly
Virtual Reality – FDA and AdComms
Eye on FDA
MAY 21, 2021
Vaccination has been robust. Cities are opening up. Plans are underway for back-to-school. Travel is robust. Offices are cautiously re-opening. There are multiple hallmarks that, whatever the consequences, we are going back to normal. The age of COVID-19 will likely continue, but with the emergence of a significant proportion of the population with vaccines pumped into them, we headed back on almost every level.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
EMA, MHRA to review Vertex' Kaftrio for children with CF
Pharma Times
MAY 20, 2021
If approved, up to 2,000 children with CF would be eligible for treatment with the drug
Healthcare bills to pay? Let hi.health pick up the tab
pharmaphorum
MAY 19, 2021
Just over a year ago, hi.health launched an app that takes the legwork out of submitting reimbursement claims to private health insurers. Now, the startup has taken another leap forward, settling users bills immediately. . Fredrik Debong. The addition to the hi.health app acts as a digital health expense account, according to the company’s co-founder and chief scientific officer Fredrik Debong, who was a co-founder of diabetes management app mySugr.com, which was snapped up by Roche in 201
Signup to get articles personalized to your interests!
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
More Trending
Artificial intelligence can elevate pharma manufacturing
Outsourcing Pharma
MAY 17, 2021
According to a leader from industrial AI specialist AspenTech, AI can help avoid costly maintenance interruptions by predicting when upkeep is needed.
NICE turns down Janssen's Erleada
Pharma Times
MAY 20, 2021
Cost-effectiveness estimates have fallen above the threshold because of uncertain trial evidence
NICE rejects J&J’s prostate cancer drug Erleada in initial guidance
pharmaphorum
MAY 20, 2021
NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The cost-effectiveness body is assessing Erleada , plus androgen deprivation therapy (ADT), for prostate cancer in adults who have hormone-relapsed non-metastatic disease at high risk of metastasising and hormone-sensitive metastatic disease.
Troubled Vaccine Maker and Its Founder Gave $2 Million in Political Donations
NY Times
MAY 18, 2021
Emergent BioSolutions faces scrutiny in Congress for ruining Covid-19 vaccines and securing lucrative federal contracts. Executives will appear before some lawmakers who benefited from the company’s spending.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Reify, SubjectWell partner to elevate trial recruitment
Outsourcing Pharma
MAY 21, 2021
The two tech-focused firms are joining forces to work on technology solutions aimed at improving patient recruitment and enrollment for various studies.
NHS England funds first national metastatic breast cancer audit
Pharma Times
MAY 21, 2021
UK-based charity Breast Cancer Now ‘proud’ of milestone after campaigning for improved data collection
UK booster trial will test value of third COVID jab dose
pharmaphorum
MAY 20, 2021
All seven COVID-19 vaccines ordered by the UK government will be tested in a new trial that will see whether they can be used as a third booster dose to protect against new variants. . The Cov-Boost trial is thought to be the first in the world to try to generate data on the value of booster doses in protecting people against COVID-19, and is being led by University Hospital Southampton NHS Foundation Trust.
New patent expiration for Sanofi Aventis drug NICODERM CQ
Drug Patent Watch
MAY 21, 2021
Annual Drug Patent Expirations for NICODERM+CQ Nicoderm Cq is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from one supplier. There is…. The post New patent expiration for Sanofi Aventis drug NICODERM CQ appeared first on DrugPatentWatch - Make Better Decisions.
Drug development advancements call for skilled workforce
Outsourcing Pharma
MAY 20, 2021
According to a leader from Saama Technologies, keeping competitive in the face of technology evolution requires staff that can keep up with the changes.
Pandemic coincided with increase in mental health problems for children
Pharma Times
MAY 18, 2021
New research suggests an association between the COVID-19 pandemic and a ‘sharp’ increase in mental health issues for 11 to 12 years olds
Report calls for better work culture in UK research
pharmaphorum
MAY 20, 2021
Create a positive working culture for the UK’s researchers, or watch the country’s standing as an innovation leader crumble, says new report. From the Oxford vaccine to the RECOVERY trial, all eyes have been on the triumph of British science in recent months. But future success is at risk if we do not create a culture that inspires and supports the next generation of researchers, says a report from the Russell Group of universities.
New patent for Otsuka Pharm drug ABILIFY MAINTENA KIT
Drug Patent Watch
MAY 21, 2021
Annual Drug Patent Expirations for ABILIFY+MAINTENA+KIT Abilify Maintena Kit is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. It is available from one supplier.…. The post New patent for Otsuka Pharm drug ABILIFY MAINTENA KIT appeared first on DrugPatentWatch - Make Better Decisions.
FDA leader: ‘stockpiling’ could transform clinical trial system
Outsourcing Pharma
MAY 18, 2021
In this third part of a series on the state of clinical research, the acting FDA commissioner talks about possible pathways to improving the infrastructure.
UK trial tests third doses of COVID-19 vaccines
Pharma Times
MAY 20, 2021
Initial results trialling seven vaccines will inform plans for Autumn booster programme
Double ransomware attack targets Irish healthcare system
pharmaphorum
MAY 17, 2021
Criminals have launched a ransomware attack against the Department of Health in Ireland, shortly after a similar cyberattack shut down much of the IT infrastructure at the Health Service Executive (HSE). . The Irish government confirmed the latest attempt yesterday, two days after the HSE was hit by a new variant of the Conti ransomware virus – thought to be run by Russia-based criminal group Wizard Spider – that was able to evade its security protocols.
New patent for Mylan Ireland drug YUPELRI
Drug Patent Watch
MAY 21, 2021
Annual Drug Patent Expirations for YUPELRI Yupelri is a drug marketed by Mylan Ireland Ltd and is included in one NDA. It is available from one supplier. There are fourteen…. The post New patent for Mylan Ireland drug YUPELRI appeared first on DrugPatentWatch - Make Better Decisions.
Digital experience impacts clinical trial success: Medallia
Outsourcing Pharma
MAY 21, 2021
A representative from the digital experience management firm discusses how improving the quality of tech interactions with patients can elevate results.
Novo Nordisk’s ziltivekimab hits primary endpoint in CKD trial
Pharma Times
MAY 18, 2021
Investigational IL-6 inhibitor reduced inflammatory biomarkers associated with atherosclerosis in CKD patients
Healios raises £7m to expand digital mental health services
pharmaphorum
MAY 18, 2021
Digital therapy specialist Healios has raised £7 million in new financing that will be used to expand its suite of mental health services, at a time when demand is soaring in the NHS. The London-based company has developed a virtual care platform that delivers a range of services targeted at children and young people with conditions such as anxiety, low mood, autism and attention-deficit hyperactivity disorder (ADHD), as well as their families.
New patent for Agios Pharms drug TIBSOVO
Drug Patent Watch
MAY 21, 2021
Annual Drug Patent Expirations for TIBSOVO Tibsovo is a drug marketed by Agios Pharms Inc and is included in one NDA. There are six patents protecting this drug. This drug…. The post New patent for Agios Pharms drug TIBSOVO appeared first on DrugPatentWatch - Make Better Decisions.
Online HPAPI Summit takes on key pharma ingredients topics
Outsourcing Pharma
MAY 19, 2021
The virtual event (scheduled June 22-24) will feature presentations from Bayer, Merck, GSK, Novartis, Takeda, FDA, WHO, and other notable organizations.
Sanofi’s Dupixent 'rapidly' improves lung function in children
Pharma Times
MAY 18, 2021
Detailed results found Dupixent improved overall asthma control in children aged six to 11 years old
From representation to empowerment: Putting patients at the centre of medicine reimbursement
pharmaphorum
MAY 17, 2021
Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps for achieving this. This article appears in full in our digital magazine Deep Dive: Market Access 2021. Read below for a sneak-peak: The reimbursement landscape in Europe is complex. There are different models, medicines are evaluated in different ways and the timelines for approval vary widely.
Experts state contract services sector the big winner of pandemic at CPhI Discover
Pharma Mirror
MAY 21, 2021
Contract services experts at this week’s CPhI Discover – (17-28th May, 2021) – the largest ever online pharma event featuring content in the opening week and networking in week two – point to pandemic contracts delivering a significant boon to the CDMO sector, but forewarn of exacerbated shortages for viral vector manufacturing. In a dedicated session three experts – Peter Shapiro Senior Director of Drugs and Business Fundamentals, PharmSource, a GlobalData Company; Eric Langer, President and Ma
Innovation drives improvement in decentralized trials: ObvioHealth
Outsourcing Pharma
MAY 20, 2021
An executive from the virtual research organization discusses the importance of advaincing studies through innovation and a patient-centric approach.
NAO report finds UK was ‘not as prepared for pandemic as it could have been’
Pharma Times
MAY 19, 2021
NHS Confederation chief exec Danny Mortimer said report ‘re-emphasises’ long-term health and social care issues
How to improve payer engagement with tailored value communication
pharmaphorum
MAY 19, 2021
Pharmaceutical drug success rests on being able to achieve market access. Brands are facing increasing pressure to demonstrate strong value propositions in increasingly crowded therapeutic areas. However, value can mean different things to different payers. In this article, Cecilie Alstad, senior analyst at Research Partnership, discusses how an approach established in the world of marketing and commercial strategy could be the key to significantly improving pharma’s payer engagement.
Ashfield Engage acquires Nuvera to enhance Patient Solutions offering
Pharma Mirror
MAY 21, 2021
Nuvera are experts in optimizing the design and build of seamless patient and HCP treatment experiences. This expertise will enhance Ashfield Engage’s Patient Solutions capabilities and create an end-to-end strategic offering across their client’s product lifecycles. Following the acquisition, Ashfield Engage and Nuvera will offer integrated specialist support and services including late-phase clinical trial experience, implementation and post-commercialization satisfaction benchmarking and serv
New patent for Genentech drug ERIVEDGE
Drug Patent Watch
MAY 20, 2021
Annual Drug Patent Expirations for ERIVEDGE Erivedge is a drug marketed by Genentech and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent for Genentech drug ERIVEDGE appeared first on DrugPatentWatch - Make Better Decisions.
Let's personalize your content